(Total Views: 239)
Posted On: 03/21/2017 8:57:20 AM
Post# of 15624
A few people tried to model the share price for OWCP and were blown away with very, very conservative numbers.
Yes, there are lots of moving parts but the upside here far outweighs the downside.
OWCP isn't a one trick pony like Axim. Once patents are issued for the delivery systems, this company will be worth Billions. That is just based on licensing agreements with other companies that want to use the sublingual tablet, topical cream, nasal spray, suppository, and condom.
Add to that the topical cream which we will see revenues for in months!
Now add to that all the other skin conditions which the topical cream can address.
Now add to that the IP for migraines, PTSD and multiple myeloma.
IMHO most people who stumbled upon OWCP are used to TRADING penny stocks. They have no good game plan because their instinct is to trade, yet all the DD they read says to instead INVEST.
It's a conflict. I'm all for playing "with the House's money", so I've done both. But my remaining shares are going to be with me for a long time. I don't see the company being fully valued until 2020 because the multiple myeloma treatment will be the biggest revenue generator IMHO.
Yes, there are lots of moving parts but the upside here far outweighs the downside.
OWCP isn't a one trick pony like Axim. Once patents are issued for the delivery systems, this company will be worth Billions. That is just based on licensing agreements with other companies that want to use the sublingual tablet, topical cream, nasal spray, suppository, and condom.
Add to that the topical cream which we will see revenues for in months!
Now add to that all the other skin conditions which the topical cream can address.
Now add to that the IP for migraines, PTSD and multiple myeloma.
IMHO most people who stumbled upon OWCP are used to TRADING penny stocks. They have no good game plan because their instinct is to trade, yet all the DD they read says to instead INVEST.
It's a conflict. I'm all for playing "with the House's money", so I've done both. But my remaining shares are going to be with me for a long time. I don't see the company being fully valued until 2020 because the multiple myeloma treatment will be the biggest revenue generator IMHO.
(2)
(0)
